Vaccine Development (Staphylococcal Infection)

Positive Interim Results in Nabi-StaphVAX Trial

Published in Medical Letter on the CDC and FDA, September 6th, 1999

Nabi, Boca Raton, Florida, announced that, based on an analysis of interim data from its pivotal clinical trial of Nabi-StaphVAX, it believes that statistical significance may be achievable at study end given the trend towards protection seen to date.

The double-blinded, placebo-controlled trial, involving 1,800 end-stage renal disease patients on hemodialysis, has been fully accrued and will continue to completion. The company anticipates that final results will be available by next summer (2000). If these results demonstrate statistical significance, Nabi will pursue U.S. Food and Drug Administration (FDA) licensure.

"We are elated that the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (1999-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry